A Phase 1 interventional study of HG146 and PD-(L)1 antibody in Solid Tumor and Lymphoma, sponsored by HitGen Inc.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by HitGen Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 276 studies in Lymphoma with a site in China — 103 open to participants now, 119 under way, 10 of them phase 3. Lymphoma · China.
Among the 276 studies in Lymphoma with a site in China, this one is the 167th largest by enrollment of the 232 interventional ones that give a count, is one of 26 that started in 2021, is one of 83 in phase 1, and was the 138th registered.
3,020 studies on the registry are indexed under Lymphoma; 435 are open to participants now.
Browse Lymphoma studies →103 of the 276 studies in Lymphoma with a site in China are open now. Recruiting first, the newest first:
Zhujiang Hospital · Sites in China
Ages 18+
Peking University First Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Guilin Medical University, China · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
Zou Dehui · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 347 Lymphoma studies recruiting now, 228 (66%) set no upper age limit and 78 (22%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
276 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 138 · Phase 2 95 · Phase 3 19 · Phase 4 12
First in 2005; this study’s year is marked. 26 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 43 across 2,320 interventional studies indexed under Lymphoma.
Median enrollment 47 across the 232 interventional studies, 366 across the 44 observational. Of the 55 that completed or were terminated, 12 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 276 have an industry lead sponsor. The 10 most frequent:
HitGen Inc. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
HitGen Inc. has 1 study filed under Lymphoma — fewer than ten, so there is no comparison to draw.
31 of the studies in Lymphoma with a site in China that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT06895538Phase 3Peking University First HospitalComparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy | 2027-02-28 |
| NCT06356129Phase 3CelgeneStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | 2027-08-09 |
| NCT06084936Phase 3Hoffmann-La RocheA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | 2027-08-31 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
Add all 31 to your calendar (.ics) → With an account.
Among the 276 studies in Lymphoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I, open-label, repeat-dose, non-randomized, multicenter study to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of HG146 administered orally (PO) alone (Part 1) or co-administered (Part 2) with PD-(L)1 inhibitor in subjects with refractory/relapsed solid tumors or Lymphoma. Part 1 consists of a dose escalation phae,Part2 consists of a dose escalation phase and a cohort expansion phase. In Part 1, escalating doses of HG146 will be evaluated as guided by the "3+3" approach. In Part 2A, escalating doses of HG146 in combination with PD-(L)1 inhibitor will be evaluated as guided by the "3+3" approach. In Part 2B, subjects will receive a single dose level of HG146 as identified based on data from Part 2, in combination with PD-(L)1 inhibitor . A total of approximately 96 subjects will be enrolled in this study, approximately 36 for dose escalation cohorts, and approximately 60 in the expansion cohorts.
Key Inclusion Criteria:
1 Subject must be >=18 years of age at the time of signing the .
2- Ia/Ib dose escalation phase(Part1 and Part 2A):Subjects with advanced/ solid tumors or Lymphoma, who have progressed on, be intolerant of, or ineligible for, all available therapies for which clinical benefit has been established.
Ib dose expansion phase(Part 2):
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. Escalating doses of HG146 will be evaluated using 3+3 approach.
Drug: HG146
Subjects will receive HG146 PO at every two days intervals (qod) for 14 consecutive days,7 days off, along with PD-(L)1 antibody IV once every 3 weeks (Q3W),21 days/ cycle. Escalating doses of HG146 in combination with PD-(L)1 antibody will be evaluated.
Drug: HG146 · Drug: PD-(L)1 antibody
Subjects who have not been treated with PD-(L)1 antibody,will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
Drug: HG146 · Drug: PD-(L)1 antibody
Subjects who have progressed on PD-(L)1 antibody, will receive HG146 po for 14 consecutive days,7 days off, in combination with PD-(L)1 antibody IV Q3W.
Drug: HG146 · Drug: PD-(L)1 antibody
HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
Also known as: HG146 capsule
PD-(L)1 Antibody is available as solution for infusion or lyophilized powder for reconstitution to be administered Q3W. It will be administered as an IV infusion for 30 minutes.
Also known as: PD-1 antibody
Part I:Dose-Limiting Toxicities (DLTs)
Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE V5.0)
Time frame: Up to 26 Days in Cycle 0 and Cycle 1
Part I:Serious Adverse Events (SAEs) and Adverse Events (AE)
Number of participants experiencing Serious Adverse Events (SAEs) and Adverse Events (AE) According to Safety performance.
Time frame: Up to 2 years
Part I:Maximum tolerated dose or Recommended Phase Ib dose (RP2D) of HG146
Maximum tolerated dose or Recommended Phase II dose of HG146 will be decided according to safety and effective results.
Time frame: Up to 2 years
Part 2A: Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)
Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE V5.0)
Time frame: Up to 21 Days in Cycle 1
Part 2A: Serious Adverse Events (SAEs) and Adverse Events (AE)
Number of participants experiencing Serious Adverse Events (SAEs) and Adverse Events (AE) According to Safety performance.
Time frame: Up to 2 years
Part 2A:Maximum tolerated dose or Recommended Phase II dose (RP2D) of HG146 in combination with PD-(L)1 antibody
Maximum tolerated dose or Recommended Phase II dose of HG146 will be decided according to safety and effective results.
Time frame: Up to 2 years
Part 1:Area under the concentration versus time curve (AUC) of HG146
Plasma concentration of HG146 will be measured following single dose and multiple dose administration
Time frame: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)
Part 1:Peak plasma concentration (Cmax) of HG146
Plasma concentration of HG146 will be measured following single dose and multiple dose administration
Time frame: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)
Part 1:Time of Cmax (Tmax) of HG146
Plasma concentration of HG146 will be measured following single dose and multiple dose administration
Time frame: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15(Except for cycle 0, each cycle is 21 days)
Part 1:Apparent terminal half-life (T1/2) of HG146
Plasma concentration of HG146 will be measured following single dose and multiple dose administration
Time frame: At the end of Cycle 0 Day 5 (Cycle 0 is 5 days);At the end of Cycle 1 Day15 (Except for cycle 0, each cycle is 21 days)
Part1: objective response rate (ORR)
ORR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)
Time frame: Up to 2 years
Part1: Best overall response (BOR)
BOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)
Time frame: Up to 2 years
Part1: Duration of response (DOR)
DOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)
Time frame: Up to 2 years
Part 1:Time-to-response (TTR)
TTR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)
Time frame: Up to 2 years
Part 1:Progression-Free Survival (PFS)
PFS will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)
Time frame: Up to 2 years
Part 2:Area under the concentration versus time curve (AUC) of HG146
Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody
Time frame: At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part 2:maximum observed plasma concentration (Cmax) of HG146
Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody
Time frame: At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part 2:time of maximum observed plasma concentration (Tmax) of HG146
Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody
Time frame: At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part 2:apparent terminal half-life (T1/2) of HG146
Plasma concentration of HG146 will be measured following multiple dose administration in combination with PD-(L)1 antibody
Time frame: At the end of Cycle 1 Day 15 (each cycle is 21 days)
Part2: objective response rate (ORR)
ORR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)
Time frame: Up to 2 years
Part2: Best overall response (BOR)
BOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)
Time frame: Up to 2 years
Part2: Duration of response (DOR)
DOR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)
Time frame: Up to 2 years
Part 2:Time-to-response (TTR)
TTR will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)
Time frame: Up to 2 years
Part 2:Progression-Free Survival (PFS)
PFS will be assessed by the Investigators using RECIST v. 1.1 or Lugano 2014( If applicable)
Time frame: Up to 2 years
Overall survival (OS)
OS will be assessed by the investigators
Time frame: Up to 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2021 to primary completion in Jun 2024, 32 months.
Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 32 months is below that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HDAC Class I/IIb Inhibitor HG146
HitGen Inc.